34486
document
Effects of losartan and enalapril on high-sensitivity C-reactive protein and total antioxidant in renal transplant recipients with Renin-Angiotensin system polymorphisms . BACKGROUND As renin-angiotensin system ( RAS ) activity may affect the severity of oxidative stress and inflammatory markers , we assessed the effects of enalapril ( E ) and/or losartan ( L ) on these markers in renal transplant recipients with RAS polymorphisms . PATIENTS AND METHODS After determination by PCR of RAS genotypes , consisting of the angiotensin-converting enzymes ( ACE I/D ) , angiotensinogens ( AGT M235T ) and angiotensin II type 1 receptors ( ATR1 A1166C ) , 76 recipients were recruited randomly and assigned 4 groups . The first ( n = 17 ) and second ( n = 24 ) groups were treated with E ( E ( + ) : 10 mg/d ) and L ( L ( + ) : 50 mg/d ) alone , respectively . The third positive control group ( n = 17 ) received E + L ( E ( + ) L ( + ) : 10 mg/d + 50 mg/d ) and the fourth negative control group ( n = 18 ) received no medication ( E ( - ) : L ( - ) ) . High-sensitivity C-reactive protein ( hs-CRP ) and total antioxidant ( TA ) inflammatory and antioxidative markers were measured after 2 months . After a 2-week washout period , the E ( + ) group was changed to L ( + ) and vice versa in a crossover design . They were followed for another 8 weeks before retesting hs-CRP and TA . A value of P < or = .05 was considered significant . RESULTS After 2 and 4 months of treatment with the drug regimen , hs-CRP and TA levels were significantly decreased and consequently increased among the E ( + ) L ( + ) , L ( + ) and E ( + ) groups ( P < .05 ) . On analyzing the relationship between RAS polymorphisms and baseline hs-CRP or TA levels , CC genotype of ATR1 showed lower hs-CRP levels ( P = .04 ) . However , none of the RAS polymorphisms predicted the antioxidant and anti-inflammatory response rates to the drugs ( P > .05 ) . CONCLUSION Although hs-CRP was lower in the CC genotype patients of ATR1 polymorphisms E and/or L reduced hs-CRP and increased TA regardless of the RAS genotype .
34487
Intervention_Pharmacological
losartan and enalapril
34488
Intervention_Pharmacological
enalapril ( E ) and/or losartan
34489
Intervention_Pharmacological
E
34490
Intervention_Pharmacological
L
34491
Intervention_Pharmacological
E + L
34492
Intervention_Pharmacological
E ( + ) L ( + ) , L ( + )
34493
Intervention_Pharmacological
E ( + )
34494
Outcome_Physical
hs-CRP
34495
Outcome_Physical
TA levels
34496
Outcome_Physical
hs-CRP levels
34497
Outcome_Physical
hs-CRP
34498
Participant_Condition
renal transplant
34499
Participant_Condition
Renin-Angiotensin system polymorphisms
34500
Participant_Condition
renal transplant
34501
Participant_Condition
RAS polymorphisms .
34502
Participant_Sample-size
76